Earnings Per Common Share

9 Months Ended

Jan. 31, 2026

Earnings Per Share [Abstract]

Earnings Per Common Share

Note 4 – Earnings Per Common Share

Net income per common and diluted share were calculated as follows for the three- and nine-month periods ended January 31, 2026 and 2025:

Schedule of Earnings Per Share

		Three Months Ended January 31, 2026				Three Months Ended January 31, 2025				Nine Months Ended January 31, 2026				Nine Months Ended January 31, 2025
Net income (loss) attributable to common stockholders – basic		$	(1,812,844	)		$	(3,006,537	)		$	(7,584,385	)		$	(7,754,208	)
Adjustments to net income			—				—				—				—
Net income (loss) attributable to common stockholders – diluted		$	(1,812,844	)		$	(3,006,537	)		$	(7,584,385	)		$	(7,754,208	)

Weighted average common shares outstanding - basic			5,612,356				1,915,367				4,432,039				1,119,479
Effect of dilutive securities			—				—				—				—
Weighted average common shares outstanding – diluted			5,612,356				1,915,367				4,432,039				1,119,479

Earnings (loss) per common share - basic		$	(0.32	)		$	(1.57	)		$	(1.71	)		$	(6.93	)
Earnings (loss) per common share - diluted		$	(0.32	)		$	(1.57	)		$	(1.71	)		$	(6.93	)

Outstanding vested warrants to purchase 2,317,723 shares of common stock are not included in the calculation of earnings per share for the three- and nine-month periods ended January 31, 2026, because their effect is anti-dilutive. Outstanding vested warrants to purchase 614,866 shares of common stock are not included in the calculation of earnings per share for the three- and nine-month periods ended January 31, 2025 because their effect is anti-dilutive.

Outstanding vested options to purchase 132,269 shares of common stock are not included in the calculation of earnings per share for the three- and nine-month periods ended January 31, 2026 because their effect is anti-dilutive.

Outstanding vested options to purchase 15,252 shares of common stock are not included in the calculation of earnings per share for the three- and nine-month periods ended January 31, 2025 because their effect is anti-dilutive.